source
- FDA questions efficacy of Capricor's Duchenne muscular dystrophy cell therapy ahead of advisory committeeFDA reviewers have raised concerns about the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy as the agency prepares for an advisory committee meeting. The agency said it could n…
- FDA says Capricor's DMD cell therapy failed to meet Phase 3 endpointsThe FDA briefing documents released before an advisory committee meeting state that the Phase 3 trial of Capricor's deramiocel did not achieve its pre-specified primary and secondary efficacy endpo…